{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:49:04Z","timestamp":1773964144014,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T00:00:00Z","timestamp":1409184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychiatr Q"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s11126-014-9319-1","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T07:05:45Z","timestamp":1409123145000},"page":"199-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Antipsychotic Medication-Induced Dysphoria: Its Meaning, Association with Typical vs. Atypical Medications and Impact on Adherence"],"prefix":"10.1007","volume":"86","author":[{"given":"Hanjing Emily","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaoluwa O.","family":"Okusaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,28]]},"reference":[{"key":"9319_CR1","first-page":"168","volume":"27","author":"C King","year":"2002","unstructured":"King C, Voruganti LN: What\u2019s in a name? The evolution of the nomenclature of antipsychotic drugs. Journal of Psychiatry and Neuroscience 27:168\u2013175, 2002.","journal-title":"J Psychiatry Neurosci"},{"key":"9319_CR2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0920-9964(99)00065-1","volume":"40","author":"PJ Harrison","year":"1999","unstructured":"Harrison PJ: The neuropathological effects of antipsychotic drugs. Schizophrenia Research 40:87\u201399, 1999.","journal-title":"Schizophr Res"},{"key":"9319_CR3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","volume":"35","author":"S Leucht","year":"1999","unstructured":"Leucht S, Pitschel-Walz G, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35:51\u201368, 1999.","journal-title":"Schizophr Res"},{"key":"9319_CR4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1192\/bjp.167.4.480","volume":"167","author":"DJ King","year":"1995","unstructured":"King DJ, Burke M, Lucas RA: Antipsychotic drug-induced dysphoria. The British Journal of Psychiatry 167:480\u2013482, 1995.","journal-title":"Br J Psychiatry"},{"key":"9319_CR5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1192\/bjp.169.4.524b","volume":"169","author":"G Lynch","year":"1996","unstructured":"Lynch G, Green JF, King DJ: Antipsychotic drug-induced dysphoria. The British Journal of Psychiatry 169:524, 1996.","journal-title":"Br J Psychiatry"},{"key":"9319_CR6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00005053-199107000-00004","volume":"179","author":"DL Noordsy","year":"1991","unstructured":"Noordsy DL, Drake RE, Teague GB, Osher FC, Hurlbut SC, Beaudett MS, et al.: Subjective experiences related to alcohol use among schizophrenics. The Journal of nervous and mental disease 179:410\u2013414, 1991.","journal-title":"J Nerv Ment Dis"},{"key":"9319_CR7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0306-4603(98)00073-2","volume":"23","author":"KT Mueser","year":"1998","unstructured":"Mueser KT, Drake RE, Wallach MA: Dual diagnosis: a review of etiological theories. Addictive Behaviors 23:717\u2013734, 1998.","journal-title":"Addict Behav"},{"key":"9319_CR8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00005053-199707000-00008","volume":"185","author":"LN Voruganti","year":"1997","unstructured":"Voruganti LN, Heslegrave RJ, Awad AG: Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. The Journal of Nervous and Mental Disease 185:463\u2013465, 1997.","journal-title":"J Nerv Ment Dis"},{"key":"9319_CR9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/002076409904500405","volume":"45","author":"AG Awad","year":"1999","unstructured":"Awad AG, Voruganti LN: Quality of life and new antipsychotics in schizophrenia. Are patients better off? International Journal of Social Psychiatry 45:268\u2013275, 1999.","journal-title":"Int J Soc Psychiatry"},{"key":"9319_CR10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0010-440X(73)90013-8","volume":"14","author":"MM Singh","year":"1973","unstructured":"Singh MM, Smith JM: Kinetics and dynamics of response to haloperidol in acute schizophrenia\u2013A longitudinal study of the therapeutic process. Comprehensive Psychiatry 14:393\u2013414, 1973.","journal-title":"Compr Psychiatry"},{"key":"9319_CR11","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1176\/ajp.136.12.1576","volume":"136","author":"ED Caine","year":"1979","unstructured":"Caine ED, Polinsky RJ: Haloperidol-induced dysphoria in patients with Tourette syndrome. The American journal of psychiatry 136:1576, 1979.","journal-title":"Am J Psychiatry"},{"key":"9319_CR12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1176\/ajp.145.5.621","volume":"145","author":"RD Bruun","year":"1988","unstructured":"Bruun RD: Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette\u2019s disorder. The American Journal of Psychiatry 145:621\u2013624, 1988.","journal-title":"The American journal of psychiatry"},{"key":"9319_CR13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/0010-440X(89)90085-0","volume":"30","author":"PJ Weiden","year":"1989","unstructured":"Weiden PJ, John Mann J, Dixon L, Haas G, Dechillo N, Frances AJ: Is neuroleptic dysphoria a healthy response? Comprehensive Psychiatry 30:546\u2013552, 1989.","journal-title":"Compr Psychiatry"},{"key":"9319_CR14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1192\/bjp.164.6.834","volume":"164","author":"JW Newcomer","year":"1994","unstructured":"Newcomer JW, Miller LS, Faustman WO, Wetzel MW, Vogler GP, Csernansky JG: Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria. The British Journal of Psychiatry 164:834\u2013838, 1994.","journal-title":"The British Journal of Psychiatry"},{"key":"9319_CR15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/070674370404900504","volume":"49","author":"AG Awad","year":"2004","unstructured":"Awad AG, Voruganti L: New antipsychotics, compliance, quality of life, and subjective tolerability\u2013are patients better off? Canadian Journal of Psychiatry 49:297\u2013302, 2004.","journal-title":"Canadian journal of psychiatry Revue canadienne de psychiatrie"},{"key":"9319_CR16","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0893-133X(01)00263-9","volume":"25","author":"L Voruganti","year":"2001","unstructured":"Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, et al: Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology 25:642\u2013650, 2001.","journal-title":"Neuropsychopharmacology"},{"key":"9319_CR17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-0447.2005.00541.x","volume":"111","author":"L Voruganti","year":"2005","unstructured":"Voruganti L, Awad AG: Brain imaging research on subjective responses to psychotropic drugs. Acta Psychiatrica Scandinavica 111:22\u201328, 2005.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"9319_CR18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-003-1648-y","volume":"171","author":"L Voruganti","year":"2004","unstructured":"Voruganti L, Awad AG: Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 171:121\u2013132, 2004.","journal-title":"Psychopharmacology (Berl)"},{"key":"9319_CR19","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1176\/ajp.136.9.1216","volume":"136","author":"ED Caine","year":"1979","unstructured":"Caine ED, Polinsky RJ: Haloperidol-induced dysphoria in patients with Tourette syndrome. The American Journal of Psychiatry 136:1216\u20131217, 1979.","journal-title":"Am J Psychiatry"},{"key":"9319_CR20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0920-9964(99)00154-1","volume":"43","author":"L Voruganti","year":"2000","unstructured":"Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A: Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 43:135\u2013145, 2000.","journal-title":"Schizophr Res"},{"key":"9319_CR21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0920-9964(01)00309-7","volume":"57","author":"L Voruganti","year":"2002","unstructured":"Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, et al.: Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophrenia Research 57:201\u2013208, 2002.","journal-title":"Schizophr Res"},{"key":"9319_CR22","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/070674370204700909","volume":"47","author":"PE Cook","year":"2002","unstructured":"Cook PE, Goldberg JO, and Van Lieshout RJ: Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Canadian Journal of Psychiatry 47:870\u2013874, 2002.","journal-title":"Can J Psychiatry"},{"key":"9319_CR23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0447.2005.00542.x","volume":"111","author":"D Naber","year":"2005","unstructured":"Naber D, Karow A, Lambert M: Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatrica Scandinavica. Supplementum 111:29\u201334, 2005.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"9319_CR24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0920-9964(00)00166-3","volume":"50","author":"D Naber","year":"2001","unstructured":"Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, et al.: Improvement of schizophrenic patients\u2019 subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 50:79\u201388, 2001.","journal-title":"Schizophr Res"},{"key":"9319_CR25","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1176\/appi.ajp.162.10.1888","volume":"162","author":"PD Harvey","year":"2005","unstructured":"Harvey PD, Rabinowitz J, Eerdeken S, Davidson M: Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. The American Journal of Psychiatry 162:1888\u20131895, 2005.","journal-title":"Am J Psychiatry"},{"key":"9319_CR26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1176\/ajp.2007.164.3.375","volume":"164","author":"SR Marder","year":"2007","unstructured":"Marder SR: Lessons from each drug trial. The American Journal of Psychiatry 164:375\u2013376, 2007.","journal-title":"Am J Psychiatry"},{"key":"9319_CR27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0447.2004.00478.x","volume":"111","author":"D Naber","year":"2005","unstructured":"Naber D. Subjective effects of antipsychotic treatment. Acta Psychiatrica Scandinavica 111:81\u201383, 2005.","journal-title":"Acta Psychiatr Scand"},{"key":"9319_CR28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1751-7893.2008.00103.x","volume":"3","author":"S Opjordsmoen","year":"2009","unstructured":"Opjordsmoen S, Melle I, Friis S, Haahr U, Johannessen JO, Larsen TK et al.: Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics. Early Intervention in Psychiatry 3:58\u201365, 2009.","journal-title":"Early Interv Psychiatry"},{"key":"9319_CR29","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1176\/appi.ajp.160.8.1405","volume":"160","author":"SR Marder","year":"2003","unstructured":"Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C et al.: Maintenance treatment of schizophrenia with risperidone or haloperidol: 2\u00a0year outcomes. American Journal of Psychiatry 160:1405\u20131412, 2003.","journal-title":"American Journal of Psychiatry"},{"key":"9319_CR30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0447.1994.tb05828.x","volume":"89","author":"A Awad","year":"1994","unstructured":"Awad A, Hogan T: Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatrica Scandinavica 89:27\u201332, 1994.","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"9319_CR31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/archpsyc.1981.01780270073010","volume":"38","author":"T Putten Van","year":"1981","unstructured":"Van Putten T, May PR, Marder SR, Wittmann LA: Subjective response to antipsychotic drugs. Archives of General Psychiatry 38:187\u2013190, 1981.","journal-title":"Archives of General Psychiatry"},{"key":"9319_CR32","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archpsyc.1978.01770280087009","volume":"35","author":"T Putten Van","year":"1978","unstructured":"Van Putten T, May R: Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Archives of General Psychiatry 35:477\u2013480, 1978.","journal-title":"Archives of General Psychiatry"},{"key":"9319_CR33","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1017\/S0033291700030282","volume":"22","author":"T Hogan","year":"1992","unstructured":"Hogan T, Awad A: Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychological Medicine 22:347\u2013352, 1992.","journal-title":"Psychol Med"},{"key":"9319_CR34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-244X-6-8","volume":"6","author":"H Ascher-Svanum","year":"2006","unstructured":"Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J: Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 6:8, 2006.","journal-title":"BMC Psychiatry"},{"key":"9319_CR35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1126\/science.278.5335.52","volume":"278","author":"GF Koob","year":"1997","unstructured":"Koob GF, Le Moal M: Drug abuse: hedonic homeostatic dysregulation. Science 278:52\u201358, 1997.","journal-title":"Science"},{"key":"9319_CR36","first-page":"1","volume":"49","author":"HC Fibiger","year":"1995","unstructured":"Fibiger HC: Neurobiology of depression: focus on dopamine. Advances in Biochemical Psychopharmacology 49:1\u201317, 1995.","journal-title":"Adv Biochem Psychopharmacol"},{"key":"9319_CR37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev.ne.18.030195.002335","volume":"18","author":"DW Self","year":"1995","unstructured":"Self DW, Nestler EJ: Molecular mechanisms of drug reinforcement and addiction. Annual Review of Neuroscience 18:463\u2013495, 1995.","journal-title":"Annu Rev Neurosci"},{"key":"9319_CR38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev.ne.19.030196.001535","volume":"19","author":"RA Wise","year":"1996","unstructured":"Wise RA: Addictive drugs and brain stimulation reward. Annual Review of Neuroscience 19:319\u2013340, 1996.","journal-title":"Annu Rev Neurosci"},{"key":"9319_CR39","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0893-133X(01)00263-9","volume":"25","author":"L Voruganti","year":"2001","unstructured":"Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, et al.: Subjective effects of AMPT induced dopamine depletion in schizophrenia; the correlation between D2 binding ratio and dysphoric responses. Neuropsychopharmacology 25:642\u2013650, 2001.","journal-title":"Neuropsychopharmacology"}],"container-title":["Psychiatric Quarterly"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-014-9319-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11126-014-9319-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-014-9319-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T06:23:35Z","timestamp":1565763815000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11126-014-9319-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,28]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["9319"],"URL":"https:\/\/doi.org\/10.1007\/s11126-014-9319-1","relation":{},"ISSN":["0033-2720","1573-6709"],"issn-type":[{"value":"0033-2720","type":"print"},{"value":"1573-6709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,28]]}}}